Targeting PI3K and/or mTOR effector proteins downstream of KRas, has been an alternative route apart from targeting the MAPK-ERK protein pathway that is synergistic with combined MAPK/ERK inhibition and similar to ERK inhibition and has overcome resistant cancer cell lines [311,312]. This evidence concerns the gene KRAS and cancer.